Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal phase II/III global study.
Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA… read more.